Pharmaceutical application of 15- or 16- substituted testosterone analogues
CA 2497838 C · Owner: Coelingh Bennink, Herman Jan Tijmen · Inventors: Bunschoten, Evert Johannes; Coelingh Bennink, Herman Jan Tijmen; Van Der Linden, Rene Frank
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to pharmaceutical dosage units for oral transmucosal or transdermal administration containing 15- or 16-substituted testosterone analogues, as well as to therapeutic methods that employ these testosterone analogues. More particularly the present invention is concerned , with such pharmaceutical dosage units containing at least 10 ~g of an androgenic steroid selected from the group consisting of 15hydroxytestosterones, 16-hydroxytestosterones precursors thereof and mixtures , of these hydroxytestosterones and/or their precursors; and a pharmaceutically acceptable excipient. The term "15-hydroxytestosterones" encompasses both 15.alpha.-hydroxytestosterone …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 5, 2003 and granted July 17, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 5, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 5, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.